Diseño de un modelo poblacional para la monitorización farmacocinética de infliximab en enfermedad inflamatoria intestinal
[EN]Anti-TNF medications have revolutionized the treatment of inflammatory bowel disease improving the symptomatology and the progress of the disease, influencing all this in the patient’s quality of life. The individual response of infliximab may be influenced by his pharmacokinetic and immunogenic...
| Autores: | , , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2018 |
| País: | España |
| Recursos: | Universidad de Salamanca (USAL) |
| Repositório: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/137758 |
| Acesso em linha: | http://hdl.handle.net/10366/137758 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Infliximab Modelo Poblacional Monitorización Farmacocinética |
| Resumo: | [EN]Anti-TNF medications have revolutionized the treatment of inflammatory bowel disease improving the symptomatology and the progress of the disease, influencing all this in the patient’s quality of life. The individual response of infliximab may be influenced by his pharmacokinetic and immunogenicity so that therapeutic concentration monitoring of the drug can guide this biologic treatments. However, there is great controversy because there is still no clear consensus in defining the therapeutic range and the most appropriate time for the performance of monitoring. The aim of this study is to justify the pharmacokinetic monitoring of infliximab and to design a preliminary population model for the monitoring and pharmacokinetic individualization of the drug in patients with inflammatory bowel disease. |
|---|